Objective To observe the effectiveness and safety of Botulinum Toxin Type A ( BTX-A) in treatment of chronic migraine. Methods A total of 39 patients with chronic migraine during September 2012 and September 2014 underwent BTX-A therapy, and all observed indexes and scores were recorded at all the different times ( before treatment, after treatment for 1 month, 2 months, 3 months and 6 months) . The statistics analysis was performed, and related ad-verse reactions were also recorded to evaluate the safety of the drug. Results The monthly values of migraine attack fre-quency, headache duration, visual analogue scales ( VAS) score of pain, headache intensity and attack numbers of head-aches patients with different degrees were significantly improved at different times after treatment compared with those be-fore treatment (P<0. 01). The lowest VAS score was found after treatment for 2 months, and the change in attack num-ber of patients with severe headaches was the most obvious one, and the headache remission was the most obvious after treatment for 2 months. The adverse reactions were observed in 4 patients without affecting their daily lives, and all were mild and reversible. Conclusion Botulinum Toxin Type A is effective and safe in treatment of patients with chronic mi-graine.%目的：观察A型肉毒毒素( BTX-A)治疗慢性偏头痛的有效性和安全性。方法选取2012年9月—2014年9月慢性偏头痛患者39例，对每例患者给予BTX-A治疗，随访记录各时段(治疗前、治疗后1、2、3、6个月)各项观察指标的结果与评分，进行统计学分析。同时记录相关不良反应，来评价该药物的安全性。结果每月偏头痛发作频率、头痛发作持续时间、疼痛视觉模拟量表( VAS)评分、头痛强度、各等级头痛人数在治疗后各时段较治疗前均有改善(P<0．01)。 VAS评分在治疗后2个月时最低，重度头痛的人数变化最明显，疼痛缓解程度在治疗后2个月最明显。本实验共发生4例不良反应，未影响日常生活，轻度可逆。结论 BTX-A治疗慢性偏头痛效果显著，在临床应用中较安全。
展开▼
